Báo cáo y học: "Diagnostic value and clinical laboratory associations of antibodies against recombinant ribosomal P0, P1 and P2 proteins and their native heterocomplex in a Caucasian cohort with systemic lupus erythematosus" pot
... 2001,
40:750-756.
doi:10.1186/ar3244
Cite this article as: Barkhudarova et al.: Diagnostic value and clinical
laboratory associations of antibodies against recombinant ribosomal P0,
P1 and P2 proteins and their native heterocomplex ... 13:R20
http://arthritis-research.com/content/13/1/R20
Page 7 of 11
RESEARCH ARTICLE Open Access
Diagnostic value and...
... and
anti-keratin antibodies reacted against citrullinated filaggrin
related proteins [8], the latter was used for detection of
ACPAs in immunoblot assays and in an ELISA, resulting in an
assay with ... AhFibA assay versus anti-CCP2 assay in population 1Scatter plot: AhFibA assay versus anti-CCP2 assay in population 1. Ab,
antibody; AhFibA = anti-human fibrinogen (auto...
... study was to examine the preva-
lence of ACPA d etected by anti-CCP2 and anti-CCP3
enzyme-linked immunosorbent assays (ELISAs), and
that of HLA-DRB1 alleles in African RA patients in
order to examine ... development of RA and of these auto-
antibodies in African RA patients. Of note, an African
specific allele of CTLA4 has recently been shown to
confer protection ag...
... line
immunoblot assays (LIAs) for single-parameter or profile anal-
ysis – have been established in clinical laboratory practice dur-
ing past years, allowing examination of a large number of sera
in a rapid ... disturbances)
and gastrointestinal involvement, renal involvement, sicca syn-
drome, joint involvement, or any other clinical symptom
assessed by the EUSTAR and...
... reactivity was
tested using a commercially available automated ELISA (EliA™
CCP Assay;Phadia GmbH, Freiburg, Germany) on a
ImmunoCAP100 automatic analyzer (Phadia AB, Uppsala,
Sweden) according to ... study was to investigate
the diagnostic accuracy of a novel and commercially available
ELISA system for the detection of antibodies against a modi-
fied citrullinated vimentin...
... LL: Rapid simultaneous diagno-
sis of infections with respiratory syncytial viruses A and B,
influenza viruses A and B, and human parainfluenza virus
types 1, 2, and 3 by multiplex quantitative ... acquisition and interpretation of clinical
data, and revised the report. AvL played a substantial role in
conceiving and designing the study and revising the manu-
s...
... 2003,
18:605-617.
42. Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T,
Itoh M, Kuniyasu Y, Nomura T, Toda M, Takahashi T: Immunologic
tolerance maintained by CD25
+
CD4
+
regulatory T cells: their
common ... assistance with the preparation of
this manuscript. This work was supported by NIH NIAID grants AI48779
and AI54610, and by grants from the American Diabetes Associ...
... (84) were assayed by using
CFFCP- and CCP2-based tests. Autoantibodies also were
analyzed at baseline and during a 2-year follow-up in 98 early RA
patients to determine their prognostic value.
Results ... 62:1135-1138.
27. Nakayama-Hamada M, Suzuki A, Furukawa H, Yamada R,
Yamamoto K: Citrullinated fibrinogen inhibits thrombin-cata-
lysed fibrin polymerization. J Biochem 2008, 14...
... unsuspected abnormalities or inciden-
tal findings. In the non -clinical research setting, any abnormal-
ity, even if finally diagnosed as benign, is a matter of medical
and ethical concern: the researcher ... formal plans to deal with the ongoing
management of these incidental lesions at many levels, incor-
porating clinical, ethical, and financial aspects. Whilst, based
on t...
... mutation in HIV-1 protease is potentially
associated with hypersusceptibility to protease
inhibitors Atazanavir and Saquinavir: is there a
clinical advantage?
Frank Wiesmann
1*
, Jan Vachta
1
, ... et al.: The L76V mutation in HIV-1
protease is potentially associated with hypersusceptibility to protease
inhibitors Atazanavir and Saquinavir: is there a clinical advantage? A...